These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19244061)

  • 1. Gadolinium-based contrast agents and nephrogenic systemic fibrosis.
    Vitti RA
    Radiology; 2009 Mar; 250(3):959; author reply 959-60. PubMed ID: 19244061
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
    Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
    Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is nephrogenic systemic fibrosis linked to the introduction of contrast-enhanced MR angiography?
    Gossner J
    Radiology; 2009 May; 251(2):612-3; author reply 613. PubMed ID: 19401586
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of nephrogenic systemic fibrosis at two large medical centers.
    Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
    Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
    Saab G; Abu-Alfa A
    AJR Am J Roentgenol; 2007 Sep; 189(3):W169. PubMed ID: 17715089
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?".
    Broome DR; Cottrell AC; Kanal E
    AJR Am J Roentgenol; 2007 Oct; 189(4):W234-5. PubMed ID: 17885040
    [No Abstract]   [Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
    J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
    Kuo PH; Kanal E; Abu-Alfa AK; Cowper SE
    Radiology; 2007 Mar; 242(3):647-9. PubMed ID: 17213364
    [No Abstract]   [Full Text] [Related]  

  • 9. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: a report of 29 cases.
    Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
    AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
    Janus N; Launay-Vacher V; Karie S; Clement O; Ledneva E; Frances C; Choukroun G; Deray G
    Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-associated nephrogenic systemic fibrosis: double dose, not single dose.
    Ng YY; Lee RC; Shen SH; Kirk G
    AJR Am J Roentgenol; 2007 Jun; 188(6):W582; author reply W583. PubMed ID: 17515358
    [No Abstract]   [Full Text] [Related]  

  • 14. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadodiamide-associated nephrogenic systemic fibrosis.
    Karlik SJ
    AJR Am J Roentgenol; 2007 Jun; 188(6):W584; author reply W585. PubMed ID: 17515359
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
    Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
    Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: chemical structure and stability of gadolinium chelates.
    Idée JM; Port M; Corot C
    Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
    Broome DR; Girguis MS; Baron PW; Cottrell AC; Kjellin I; Kirk GA
    AJR Am J Roentgenol; 2007 Feb; 188(2):586-92. PubMed ID: 17242272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.